NTRK1 and mesenchymal cell neoplasm: During our routine molecular diagnostic work up (period 2022–2024), we found a non-pathogenic PRCC::NTRK1-rearrangement in 12 patients with mesenchymal neoplasms using a custom-made ArcherTM FusionPlexTM Sarcoma Panel.